The startup develops a recombinant targeted immunomodulator platform specifically for treating ovarian cancer and small cell lung cancer. This technology addresses the need for effective therapies in oncology by providing healthcare providers with targeted treatment options for patients with unmet medical needs.
Funding
Funding not disclosed
Founders
Product
Problem
Ovarian cancer and small cell lung cancer are highly aggressive malignancies with significant unmet medical needs, requiring more effective and targeted therapeutic interventions. Current treatment options often lack specificity, leading to systemic toxicities and limited efficacy, especially for patients with advanced or recurrent disease.
Solution
OmniCyte is a preclinical-stage biotechnology company developing recombinant targeted immunomodulators for cancer therapy. Their proprietary Immuno-Oncology Platform Technology focuses on co-stimulatory molecules designed to selectively activate the immune system within the tumor microenvironment. By targeting specific cancer cell markers, OmniCyte's immunomodulators aim to enhance anti-tumor immune responses while minimizing off-target effects. This approach has the potential to improve treatment outcomes and reduce the side effects associated with traditional cancer therapies. The platform is being developed for ovarian cancer, small cell lung cancer, and multiple additional indications.
Target Audience
The primary target audience includes healthcare providers specializing in oncology, particularly those treating patients with ovarian cancer and small cell lung cancer, as well as clinical researchers in the field of immuno-oncology.
Features
- Recombinant targeted immunomodulators designed to co-stimulate the immune system
- Focus on ovarian cancer and small cell lung cancer indications
- Platform applicable to non-small cell lung cancer, glioma, cancer stem cells, pancreatic, prostate, and leukemia
- Targeted approach to minimize off-target effects and systemic toxicities
- Immuno-oncology platform designed to enhance anti-tumor immune responses